PREDICT. ENGINEER. OUTCOMPETE PATHOGENS.
Embedded Files
We redesign natural bacterial-produced nanoparticles, called tailocins, into precise and potent drug candidates that treat antibiotic-resistant infections.
Electron micrograph of a natural tailocin (ca. 200 nm). Our software-in-development redesigns this natural nanotech into a precision antibiotic
Tailocins are nature's nanotech used by bacteria to outcompete their close kin
Our IP-protected, AI-powered platform redesigns tailocins for their subsequent development into safe and effective precision drugs
Elakistos feature by NtbkLM.wavLooking to partner with us?
Get in touch: info@elakistosbiosciences.com
Endorsements
Elakistos Biosciences is among the few selected AI+Biotech start-ups in the June 2025 cohort of the global and insight-filled Next Sequence accelerator program
Elakistos Biosciences was one of Bpifrance EuroQuity's top deeptech start-ups selected for their April 2025 SEADE DEEPTECH E-PITCH.
Check out our 5-min pitch in the youtube video link found here
Elakistos Biosciences was awarded the best scientific research in the National Research Fund 2024 Kenya National Research Festival Poster Category.
Resources
bioRxiv 2025.04.19.648921; doi: https://doi.org/10.1101/2025.04.19.648921
BMC Genomics 25, 1087 (2024). https://doi.org/10.1186/s12864-024-10858-2
Access Microbiology 5, 10 (2023); https://doi.org/10.1099/acmi.0.000659.v3.
Access Microbiology. 5, 5 (2023); https://doi.org/10.1099/acmi.0.000531.v4.
Front Microbiol. 13, 993688 (2022) doi: 10.3389/fmicb.2022.993688.
Page updated
Report abuse